CAS:91396-88-2
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:Light yellow to khaki Solid
是一种酰基-辅酶A去饱和酶 (SCD) 抑制剂,是一种多能细胞特异性的抑制剂。
Array ( [133] => Array ( [id] => 133 [name] => Inhibitors & Antagonists & Agonists [num] => 3416 [children] => Array ( [352] => Array ( [id] => 352 [name] => Protein Tyrosine Kinase/PTK ) [350] => Array ( [id] => 350 [name] => PI3K/Akt/mTOR ) [351] => Array ( [id] => 351 [name] => Endocrinology & Hormones ) [357] => Array ( [id] => 357 [name] => Angiogenesis ) [358] => Array ( [id] => 358 [name] => HIF ) [363] => Array ( [id] => 363 [name] => Immunology & Inflammation ) [364] => Array ( [id] => 364 [name] => Stem Cells ) [365] => Array ( [id] => 365 [name] => Apoptosis ) [377] => Array ( [id] => 377 [name] => Metabolic Enzyme & Protease ) [379] => Array ( [id] => 379 [name] => Autophagy ) [380] => Array ( [id] => 380 [name] => ER Stress ) [384] => Array ( [id] => 384 [name] => Cell Cycle ) [385] => Array ( [id] => 385 [name] => Cytoskeleton ) [386] => Array ( [id] => 386 [name] => DNA Damage & DNA Repai ) [387] => Array ( [id] => 387 [name] => Epigenetics ) [388] => Array ( [id] => 388 [name] => Ubiquitin ) [389] => Array ( [id] => 389 [name] => JAK/STAT ) [390] => Array ( [id] => 390 [name] => GPCR & G Protein ) [391] => Array ( [id] => 391 [name] => Neuronal Signal Pathway ) [392] => Array ( [id] => 392 [name] => MAPK ) [393] => Array ( [id] => 393 [name] => NF-κB ) [394] => Array ( [id] => 394 [name] => Membrane Transporter & Ion Channel ) [395] => Array ( [id] => 395 [name] => TGF-β/Smad ) [396] => Array ( [id] => 396 [name] => Hippo ) [775] => Array ( [id] => 775 [name] => Antibody-drug Conjugate/ADC Related ) [122] => Array ( [id] => 122 [name] => Others ) ) ) )
>
Small Molecule Compounds >
Inhibitors & Antagonists & Agonists >
Metabolic Enzyme & Protease >
PluriSIn 1CAS:91396-88-2
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:Light yellow to khaki Solid
CAS | 91396-88-2 |
Chinese Name | N'-苯基异烟肼 |
English Name | PluriSIn 1 |
Synonyms | 4-吡啶羧酸 2-苯基酰肼;NSC 14613 |
Molecular Formula | C12H11N3O |
Molecular Weight | 213.24 |
Solubility | Soluble in DMSO ≥5mg/mL(Need ultrasonic) |
Purity | ≥98% |
Appearance | Light yellow to khaki Solid |
Storage | Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
EC | EINECS 804-702-5 |
MDL | MFCD00026984 |
SMILES | O=C(C1=CC=NC=C1)NNC2=CC=CC=C2 |
Target Point | Stearoyl-CoA Desaturase (SCD) |
Passage | Metabolic Enzyme&Protease |
Background | PluriSIn 1 is an acyl-CoA desaturase (SCD) inhibitor that is specific for pluripotent cells. |
Biological Activity | PluriSln 1 是一种酰基-辅酶A去饱和酶 (SCD) 抑制剂,是一种多能细胞特异性的抑制剂。[1] |
In Vitro | PluriSln 1,硬脂酰辅酶A去饱和酶(SCD)的小分子抑制剂,诱导多能干细胞(iPS)来源的心肌细胞(CM)。 PluriSln 1处理显着降低Nanog的mRNA和蛋白水平,Nanog是细胞多能性和肿瘤进展的标志物;重要的是,我们提供证据表明PluriSln 1在20μM处理1天显着诱导Nanog阳性iPS衍生物(iPSD)的细胞凋亡。此外,PluriSln 1在20μM处理4天减少培养的iPSD中的Nanog阳性干细胞,同时不增加iPS衍生的CM的凋亡。为了研究PluriSln 1处理是否预防细胞移植后iPSD的致瘤性,我们在心肌梗塞(MI)的小鼠模型中心肌内注射PluriSln 1-或DMSO-处理的iPSD。 DMSO处理的iPSD在注射后2周容易形成表达Nanog的肿瘤,这通过用PluriSln 1处理来预防。此外,用PluriSln 1处理不改变心脏标志物cTnI,α-MHC或MLC-2v的表达。分化(P> 0.05,n = 4)。重要的是,PluriSln 1处理的iPS衍生的CM表现出在梗塞的心肌中移植和存活的能力[1]。 |
Cell Experiment | iPS细胞向心肌细胞(CM)的分化由胚状体(EB)形成诱导。当iPS细胞在10-cm培养皿中达到70%汇合时,使用0.25%胰蛋白酶/ EDTA消化细胞。将细胞沉淀重悬于分化培养基(含有20%FBS和10ng / mL BMP4的DMEM)中至终浓度为200,000个细胞/ mL。将细胞悬浮液加入具有Ulta-Low Attachment表面的6孔板中4天以引发EB形成。在第5天,使用CF培养基将EB在0.1%明胶包被的培养皿上培养14天,用于心脏结构的生长。在这个阶段,经历EB形成的iPS细胞被称为iPS衍生物(iPSD)[1]。 |
Data Literature Source | [1]. Zhang L,et al. Inhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: improving the safety of iPS cell transplantation to myocardium. Cell Cycle. 2014;13(5):762-71 |
Unit | Bottle |
Specification | 5mg 10mg |
是一种酰基-辅酶A去饱和酶 (SCD) 抑制剂,是一种多能细胞特异性的抑制剂。